Form 8-K - Current report:
SEC Accession No. 0000950170-24-092270
Filing Date
2024-08-07
Accepted
2024-08-07 07:07:39
Documents
14
Period of Report
2024-08-07
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K tngx-20220810.htm   iXBRL 8-K 42561
2 EX-99.1 tngx-ex99_1.htm EX-99.1 171419
3 GRAPHIC img21139354_0.jpg GRAPHIC 26351
4 GRAPHIC img159114951_0.jpg GRAPHIC 778
  Complete submission text file 0000950170-24-092270.txt   411079

Data Files

Seq Description Document Type Size
5 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT tngx-20220810.xsd EX-101.SCH 48916
17 EXTRACTED XBRL INSTANCE DOCUMENT tngx-20220810_htm.xml XML 4873
Mailing Address 201 BROOKLINE AVENUE SUITE 901 BOSTON MA 02215
Business Address 201 BROOKLINE AVENUE SUITE 901 BOSTON MA 02215 (857) 320-4900
Tango Therapeutics, Inc. (Filer) CIK: 0001819133 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39485 | Film No.: 241181398
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)